Cold Agglutinin Disease

A chronic complement-mediated disease, driven by an IgM-producing clone, where treatment decisions depend more on trajectory and clinical impact than on laboratory thresholds.

Cold agglutinin disease is a chronic complement-mediated hemolytic anemia in which the mechanism is relatively clear but management is rarely automatic. Patients often live for years with fluctuating symptoms, seasonal triggers, and variable clinical impact. Understanding CAD requires more than knowing its biology. It requires understanding how a clonal process drives complement-mediated hemolysis, and how that biology translates into clinical decisions: how clinicians interpret findings, weigh trade-offs, and decide when to intervene, and whether to target the hemolysis or the underlying clone.

Start Here

This module is organized to reflect how clinicians understand and manage cold agglutinin disease. It begins with foundational concepts and clinical presentation, then moves through diagnosis and treatment. Later sections explore uncertainty, patient experience, evidence interpretation, and applied clinical reasoning. You do not need to read everything in order, but if you are new to CAD, the pathway below is the best place to start.

Recommended starting path
Definitions → Clinical Presentation → Diagnosis → Treatment Strategy